2-巯基-2-甲基-1-丙胺 | 7684-18-6

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醇
• 中文名称: 2-巯基-2-甲基-1-丙胺
• 英文名称: 2-mercapto-2-methyl-1-propylamine
• 英文别名: 1-amino-2-methylpropane-2-thiol；2-mercapto-2-methylpropylamine
• CAS: 7684-18-6
• 化学式: C₄H₁₁NS
• mdl: MFCD13193749
• 分子量: 105.204
• InChiKey: MBPAUMHSIFBANF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  6
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  27
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-巯基-2-甲基-1-丙胺 在 4,4'-Dithio-bis-benzolsulfonsaeure 作用下， 生成 2,2,5,5-Tetramethyl-3,4-dithiahexane-1,6-diamine
  参考文献：
  名称：

  Rate constants and equilibrium constants for thiol-disulfide interchange reactions involving oxidized glutathione

  摘要：

  DOI：

  10.1021/ja00526a042
• 作为产物：
  描述：

  2,2'-dimethyl-2,2'-disulfanediyl-bis-propionaldehyde dioxime 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 15.0h， 生成 2-巯基-2-甲基-1-丙胺
  参考文献：
  名称：

  New Thionitrites: Synthesis, Stability, and Nitric Oxide Generation

  摘要：

  In order to study the influence of substitutions at the alpha and beta carbon atoms on the stability of the S-NO bond, water-soluble thionitrites RSNO have been synthesized by nitrosation of cysteamine and mercaptoethanol derivatives and characterized. H-1 and C-13 NMR spectroscopies have proven to be excellent probes for the nitrosation of thiols. In water, at physiological pH, the compounds decomposed into nitric oxide NO and the corresponding disulfides. The rate at which NO was released was very sensitive to modifications at the alpha and beta carbon atoms. Tertiary thionitrites were more stable than primary thionitrites. The beta-substituents decreased the rates of decomposition in the following order: OH > NHCOCH3 > NH3+. S-Nitrosocysteamine derivatives were greatly stabilized at low pH. The compounds described here might be convenient and useful as vehicles for spontaneous generation of nitric oxide in biological systems, at rates that can be finely tuned and controlled over a wide range.

  DOI：

  10.1021/jo00102a028

文献信息

• Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
  申请人：——

  公开号：US20010041726A1

  公开（公告）日：2001-11-15

  The present invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or optionally, at least one therapeutic agent, such as, steroids, nonsteroidal antiinflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B 4 (LTB 4 ) receptor antagonists, leukotriene A 4 (LTA 4 ) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) inhibitors, H antagonists, antineoplastic agents, antiplatelet agents, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pylori inhibitors, proton pump inhibitors, isoprostane inhibitors, and mixtures thereof. The present invention also provides novel compositions comprising at least one parent COX-2 inhibitor and at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The present invention also provides kits and methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 inhibitors; for facilitating wound healing; for treating and/or preventing renal toxicity; and for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2.

  本发明描述了新颖的硝化和/或亚硝化环氧合酶2（COX-2）抑制剂以及包含至少一种硝化和/或亚硝化环氧合酶2（COX-2）抑制剂的新型组合物，以及可选地，至少一种捐赠、转移或释放一氧化氮、刺激内源性一氧化氮合成、提高内源性内皮源性舒张因子水平或是一氧化氮合酶底物的化合物，和/或可选地，至少一种治疗剂，如类固醇、非甾体抗炎化合物（NSAID）、5-脂氧合酶（5-LO）抑制剂、白三烯B4（LTB4）受体拮抗剂、白三烯A4（LTA4）水解酶抑制剂、5-HT激动剂、3-羟基-3-甲基戊二酰辅酶A（HMGCoA）抑制剂、H受体拮抗剂、抗肿瘤药物、抗血小板药物、解充血剂、利尿剂、镇静或非镇静抗组胺药、诱导型一氧化氮合酶抑制剂、阿片类药物、镇痛剂、幽门螺杆菌抑制剂、质子泵抑制剂、异前列腺素抑制剂以及其混合物。本发明还提供了包含至少一种母体COX-2抑制剂和至少一种一氧化氮供体的新型组合物，以及可选地，至少一种治疗剂。本发明还提供了用于治疗炎症、疼痛和发热的工具和方法；用于治疗和/或改善COX-2抑制剂的胃肠道特性；用于促进伤口愈合；用于治疗和/或预防肾毒性；以及用于治疗和/或预防由于环氧合酶-2水平升高而导致的其他疾病的工具和方法。
• 一种含二硫键的两性霉素B衍生物及其用途
  申请人：深圳市儿童医院

  公开号：CN111875653A

  公开（公告）日：2020-11-03

  本发明公开了一种含二硫键的两性霉素B衍生物，拓宽了现有抗菌化合物的范围，可作为先导化合物继续优化。同时本发明化合物具有良好的抗菌活性，其抗菌活性比两性霉素B更好；相对于两性霉素B而言，具有更低的血液毒性和细胞毒性，在保持抗菌活性的同时可以减少两性霉素对于人体的毒副作用。
• Synthesis of pentadentate mixed dithiolate chelating ligands derived from heterocycles and 2-mercaptoethylamines
  作者：Zongren Zhang、Arthur E. Martell、Ramunas J. Motekaitis、Lixia Fu

  DOI：10.1016/s0040-4039(99)00757-1

  日期：1999.6

  reductive amination of 2,6-pyridinedialdehyde with 2-mercaptoethylamines. Reaction of 2,5-thiophenedicarbonyl chloride with 2-mercaptoethylamines led to N,N′-bis(substituted-2-thioethyl)-2,5-thiophenedicarboxamides. 2,6-Bis-((substituted-2-thioethyl)aminomethyl)pyridines and N,N′-bis(substituted-2-thioethyl)-2,5-thiophenedicarboxamides are novel pentadentate mixed dithiolate chelating reagents which can

  2，6-吡啶二醛与2-巯基乙胺或2-烷基硫代乙胺的缩合产生2，6-双（取代的2-噻唑烷基）吡啶或2，6-双-（（（2-烷基-硫代）乙基亚氨基）甲基吡啶。噻唑烷可以还原地打开，得到2，6-双-（（取代的-2-硫代乙基）氨基甲基）吡啶。或者，后者可以通过2，6-吡啶二醛与2-巯基乙胺的还原胺化来合成。2，5-噻吩二羰基氯与2-巯基乙胺的反应生成N，N′-双（取代的-2-硫乙基）-2，5-噻吩二甲酰胺。2,6-双-（（取代-2-硫乙基）氨基甲基）吡啶和N，N'-双（取代-2-硫乙基）-2,5-噻吩二甲酰胺是新颖的五齿混合物 可以形成具有仿生重要性的铁配合物的二硫醇盐螯合剂。
• Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use
  申请人：NitroMed, Inc.

  公开号：US06297260B1

  公开（公告）日：2001-10-02

  The present invention describes novel nitrosated and/or nitrosylated nonsteroidal antiinflammatory compounds, and novel compositions comprising at least one nitrosated and/or nitrosylated nonsteroidal antiinflammatory compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The present invention also provides methods for treating, preventing and/or reducing inflammation, pain, and fever; decreasing or reversing the gastrointestinal, renal and other toxicities resulting from the use of nonsteroidal antiinflammatory drugs; treating and/or preventing gastrointestinal disorders; treating inflammatory disease states and disorders; and treating and/or preventing ophthalmic diseases or disorders.

  本发明描述了新颖的硝化和/或亚硝化非甾体抗炎化合物，以及包含至少一种硝化和/或亚硝化非甾体抗炎化合物的新型组合物，还可以包含至少一种捐赠、转移或释放一氧化氮、提高内源性内皮源性舒张因子水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物的化合物。本发明还提供了治疗、预防和/或减轻炎症、疼痛和发热的方法；减少或逆转使用非甾体抗炎药物导致的胃肠道、肾脏和其他毒性反应；治疗和/或预防胃肠道疾病；治疗炎症性疾病状态和疾病；以及治疗和/或预防眼科疾病或疾病的方法。
• [EN] FATTY ACID CYSTEAMINE CONJUGATES OF CFTR MODULATORS AND THEIR USE IN TREATING MEDICAL DISORDERS<br/>[FR] CONJUGUÉS DE CYSTÉAMINE D'ACIDE GRAS DE MODULATEURS DE CFTR ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：CATABASIS PHARMACEUTICALS INC

  公开号：WO2016086136A1

  公开（公告）日：2016-06-02

  The invention relates to fatty acid cysteamine conjugates of a CFTR modulator, compositions comprising a fatty acid cysteamine conjugate of a CFTR modulator, and methods for using such conjugates and compositions to treat disease, such as a disease caused by dysregulation of autophagy.

  这项发明涉及一种CFTR调节剂的脂肪酸半胱氨酸共轭物，包括CFTR调节剂的脂肪酸半胱氨酸共轭物的组合物，以及使用这种共轭物和组合物治疗疾病的方法，例如由自噬失调引起的疾病。